Pricing Information
Like many patients, knowing what you may pay for treatment can be a major concern. That’s why
Bristol Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP)
costs and possible resources that may help make them more affordable.
The information below will help you understand not only the list price of your medication, but what
your out-of-pocket (OOP) costs might be based on your infusion schedule and insurance coverage.
Click below to learn more about your medication cost based on your infusion schedule and insurance coverage.
-
The list price for an OPDIVO 3 mg/kg + YERVOY 1 mg/kg infusion is $25,041 and the list price for an OPDIVO 3 mg/kg alone infusion is $7,635.* However, most patients will pay less than the list price. In fact, about 70% of patients paid an average of $25 or less in 2023 for FDA-approved uses of the combination infusion of OPDIVO + YERVOY.†
-
For certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1, your doctor may initiate the following treatment schedule: OPDIVO 3 mg/kg every 2 weeks and YERVOY 1 mg/kg every 6 weeks. This combination will continue for up to 2 years or as instructed by your doctor.
The information below will help you better understand what you could pay for your medication based on your insurance coverage.
-
If you have commercial insurance
You could pay as little as $0 per medication per infusion with the BMS Oncology Co-pay Assistance Program. Learn about this program.
-
If you have Medicare
Depending on your specific Medicare benefits, you may pay 0-20% of the medication list price. If you have Medicare Part B, you may also have a supplemental insurance plan that may pay all or part of your OPDIVO or OPDIVO + YERVOY cost. If you have Medicare Part C, there is an out-of-pocket total Medical Expense maximum, so what you will pay for your medication will depend on your plan’s benefit design and the level of your other healthcare expenses during the year. Please check with your Medicare plan administrator for more details and to understand your specific costs.
-
If you have Medicaid
You could pay $0-$20 per medication, per infusion (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
-
If you do not have insurance coverage
If you do not have medical coverage or your insurance does not cover OPDIVO + YERVOY, you could expect to pay the list price shown above. Patients without insurance are encouraged to call 1-855-OPDIVO-1 to explore potential options.
For additional information, the BMS Access Support® program provides resources to help patients understand their insurance coverage and find information on sources of financial support.
As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program may help eligible commercially insured patients pay only $0 per medication per infusion. BMS will cover the rest of the cost, up to $25,000 per year per product.
Please visit BMS Access Support or call BMS Access Support at 1-800-861-0048, 8 am to 8 pm ET, Monday to Friday.
For certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC), your doctor may choose to prescribe OPDIVO + YERVOY + chemotherapy with the following treatment schedule: OPDIVO 360 mg every 3 weeks + YERVOY 1 mg/kg every 6 weeks
The list price for an OPIVO 360 mg and YERVOY 1 mg/kg infusion is $28,858 and the list price for an OPDIVO 360 mg alone infusion is $11,452.* However, most patients will pay less than the list price.
Please see the above information to help you better understand what you could pay for your medication based on your insurance coverage.
*This price does not include the cost of administration, biomarker testing and other medicines, or infusion center costs. This list price is current as of 07/01/2024. The price for weight-based dosing may vary depending on the patient’s weight. The pricing for OPDIVO 3 mg/kg and YERVOY 1 mg/kg is based on an 80 kg patient.
†As of 2022, the approved uses of the combination infusion of OPDIVO + YERVOY were advanced renal cell carcinoma, metastatic melanoma, MSI-H/dMMR metastatic colorectal cancer, advanced hepatocellular carcinoma, PD-L1 ≥1% metastatic non-small cell lung cancer, recurrent or metastatic non-small cell lung cancer, and malignant pleural mesothelioma, and metastatic esophageal squamous cell carcinoma.
For most OPDIVO + YERVOY combination indications, there are two phases in the recommended dosing schedule.
PHASE 1
Treatment has a maximum of 4 infusion visits that include both OPDIVO and YERVOY. The list price for OPDIVO + YERVOY* ranges from $25,677–$46,060 depending on the dose your doctor has prescribed.
PHASE 2
Treatment continues with just OPDIVO alone. For patients receiving OPDIVO 240 mg every 2 weeks, the list price is $7,635 per infusion.† For patients receiving OPDIVO 480 mg every 4 weeks, the list price is $15,269 per infusion period.
The dosing schedule for malignant pleural mesothelioma (MPM) does not follow the 2-phased schedule noted above. For adult patients being treated with OPDIVO + YERVOY newly diagnosed with MPM that cannot be removed by surgery, your doctor may initiate the following treatment schedule: OPDIVO 360 mg every 3 weeks + YERVOY 1 mg/kg every 6 weeks. The list price for OPDIVO 360 mg and YERVOY 1 mg/kg infusion is $28,858.
-
If you have commercial insurance
You could pay as little as $0 per medication with the BMS Oncology Co-pay Assistance Program. Learn about this program
-
If you have Medicare
Depending on your specific Medicare benefits, you may pay 0-20% of the medication list price. If you have Medicare Part B, you may also have a supplemental insurance plan that may pay all or part of your OPDIVO or OPDIVO + YERVOY cost. If you have Medicare Part C, there is an out-of-pocket total Medical Expense maximum, so what you will pay for your medication will depend on your plan's benefit design and the level of your other healthcare expenses during the year. Please check with your Medicare plan administrator for more details and to understand your specific costs.
-
If you have Medicaid
You could pay $0-$20 per medication (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
-
If you do not have insurance coverage
If you do not have medical coverage or your insurance does not cover OPDIVO + YERVOY, you can expect to pay the list price shown above. Patients without insurance are encouraged to call 1-855-OPDIVO-11-855-OPDIVO-1 to explore potential options.
For additional information, the BMS Access Support® program provides resources to help patients understand their insurance coverage and find information on sources of financial support.
As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program may help eligible commercially insured patients pay only $0 per medication. BMS will cover the rest of the cost, up to $25,000 per year per product.
Please visit BMS Access Support or call BMS Access Support at 1-800-861-00481-800-861-0048, 8 AM to 8 PM ET, Monday to Friday.
*The list price and Medicare range for OPDIVO + YERVOY combination therapy is based on the approved induction phase for either advanced renal cell carcinoma (RCC), advanced (metastatic) melanoma, or colorectal cancer (MSI-H/dMMR) and is current as of July 1, 2024. The price for weight-based dosing may vary depending on the patient’s weight. For RCC and CRC, the pricing for OPDIVO 3 mg/kg and YERVOY 1 mg/kg is based on an 82.5 kg patient. For metastatic melanoma, the pricing for OPDIVO 1 mg/kg and YERVOY 3 mg/kg is based on an 80 kg patient. For patients being treated with OPDIVO + YERVOY for advanced hepatocellular carcinoma (HCC), your doctor may initiate the following treatment schedule: OPDIVO 1 mg/kg every 3 weeks + YERVOY 3 mg/kg every 3 weeks based on a 66.5 kg patient. After 9 weeks, the treatment schedule may continue as follows: OPDIVO 240 mg every 2 weeks or OPDIVO 480 mg every 4 weeks. This price does not include the cost of administration and other medicines or infusion center costs.
†The list prices are current as of July 1, 2024.
For patients receiving OPDIVO 240 mg every 2 weeks, the list price is $7,635 per infusion.* For patients receiving OPDIVO 480 mg every 4 weeks, the list price is $15,269. However, most patients will pay less than the list price.
The information below will help you better understand what you could pay for your medication based on your insurance coverage.
-
If you have commercial insurance
You could pay as little as $0 per medication per infusion with the BMS Oncology Co-pay Assistance Program. Learn about this program.
-
If you have Medicare
Depending on your specific Medicare benefits, you may pay 0-20% of the medication list price. If you have Medicare Part B, you may also have a supplemental insurance plan that may pay all or part of your OPDIVO cost. If you have Medicare Part C, there is an out-of-pocket total Medical Expense maximum, so what you will pay for your medication will depend on your plan's benefit design and the level of your other healthcare expenses during the year. Please check with your Medicare plan administrator for more details and to understand your specific costs.
-
If you have Medicaid
You could pay $0-$20 per infusion (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
-
If you do not have insurance coverage
If you do not have medical coverage or your insurance does not cover OPDIVO, you could expect to pay the list price shown above. Patients without insurance are encouraged to call 1-855-OPDIVO-11-855-OPDIVO-1 to explore potential options.
For additional information, the BMS Access Support® program provides resources to help patients understand their insurance coverage and find information on sources of financial support.
As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program may help eligible commercially insured patients pay only $0 per medication. BMS will cover the rest of the cost, up to $25,000 per year per product.
Please visit BMS Access Support or call BMS Access Support at 1-800-861-00481-800-861-0048, 8 AM to 8 PM ET, Monday to Friday.
*The list prices are current as of July 1, 2024. The prices listed above do not include the cost of administration and other medicines or infusion center costs.
FULL INDICATIONS
For certain adults with advanced
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
OPDIVO (10 mg/mL) and YERVOY
(IV)
use.
For adults with early-stage non-small cell lung cancer (NSCLC) before surgery
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).
For adults with previously treated advanced non-small cell lung cancer
OPDIVO® (nivolumab) is a prescription medicine
used to treat adults with a type of advanced stage lung cancer
(called non-small cell lung cancer) that has spread or grown
and you have tried chemotherapy that contains
platinum, and it did not work or is no longer working. If your
tumor has an abnormal EGFR or ALK gene, you should have also
tried an
For adults and children 12 years of age and older with advanced melanoma
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
OPDIVO (10 mg/mL) and YERVOY
(IV)
use.
For adults and children 12 years of age and older with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
For certain adults with advanced kidney cancer (renal cell carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
For adults with previously treated advanced kidney cancer (renal cell carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
For adults with previously treated squamous cell carcinoma of the head and neck
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.
For adults with liver cancer (hepatocellular carcinoma) who have received treatment with sorafenib
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.
OPDIVO (10 mg/mL) and YERVOY
(IV)
use.
For adults with previously treated advanced cancer in the bladder or urinary tract (urothelial carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis) [urothelial carcinoma] when it has spread or grown (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.
For adults with a type of bladder or urinary tract cancer (urothelial carcinoma) to help prevent it from coming back after it was removed by surgery
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.
For people 12 years of age and older whose CRC has spread to other parts of the body (metastatic); has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; and is MSI-H or dMMR
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections
for intravenous
(IV) use.
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.
For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.
For adults newly diagnosed with malignant pleural mesothelioma (MPM)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for
intravenous
(IV) use.
For adults with previously treated advanced esophageal squamous cell cancer
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.
For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back
OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
For previously untreated adults with advanced or metastatic esophageal squamous cell cancer (ESCC)
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery (advanced) or has spread to other parts of the body (metastatic) and you have not already had treatment for your advanced or metastatic esophageal cancer.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery (advanced) or has spread to other parts of the body (metastatic), and you have not already had treatment for your advanced or metastatic esophageal cancer.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
For certain previously untreated adults with advanced gastric, gastroesophageal junction, and esophageal adenocarcinomas
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric), junction between the stomach and esophagus (gastroesophageal junction), and esophagus that is a type called adenocarcinoma and cannot be removed with surgery or has spread to other parts of the body.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
Important Facts About OPDIVO® (nivolumab) and
OPDIVO + YERVOY® (ipilimumab)
This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY. Your healthcare team can work with you to help answer any questions you may have about these medications. Keep this information in a safe place so you can refer to it before and during your treatment.
Look out for the following icons as you read:
Talk to your
healthcare team
Call a healthcare
provider right away
Helpful information
to remember
-
Talk to your
healthcare team -
Call a healthcare
provider right away -
Helpful information
to remember
What is the most important information I should know about OPDIVO + YERVOY?
OPDIVO and YERVOY are medicines that may treat certain cancers by working with your immune system. OPDIVO and YERVOY can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. Some of these problems may happen more often when OPDIVO is used in combination with another therapy.
Get medical help immediately if you develop any of these signs or symptoms or they get worse. It may keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment and may treat you with corticosteroid or hormone replacement medicines. If you have severe side effects, your healthcare team may also need to delay or completely stop your treatment.
What are the serious side effects of OPDIVO and
OPDIVO + YERVOY?
A serious side effect is a side effect that can sometimes become severe or life-threatening and can lead to death. They may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
Lung problems — Things to look out for may include:
- new or worsening cough
- shortness of breath
- chest pain
Intestinal problems — Things to look out for may include:
- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdominal) pain or tenderness
Liver problems — Things to look out for may include:
- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal
Hormone gland problems — Things to look out for may include:
- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems — Things to look out for may include:
- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite
Skin problems — Things to look out for may include:
- rash
- itching
- skin blistering or peeling
- painful sores or ulcers in the mouth or nose, throat, or genital area
Eye problems — Things to look out for may include:
- blurry vision, double vision, or other vision problems
- eye pain or redness
Problems can also happen in other organs and tissues. These are not all the signs and symptoms of immune system problems that can happen with OPDIVO and YERVOY. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:
- Chest pain, irregular heartbeat, shortness of breath, swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising
What are the possible side effects of OPDIVO + YERVOY?
OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:
See the previous section, “What is the most important information I should know about OPDIVO + YERVOY?”
Severe infusion reactions — Things to look out for may include:
- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feel like passing out
- fever
- back or neck pain
Tell your healthcare team right away if you get these symptoms during an infusion of OPDIVO or YERVOY.
Complications, including graft-versus-host disease (GVHD), of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO or YERVOY. Your healthcare provider will monitor you for these complications.
What are the most common side effects?
The most common side effects of OPDIVO when used alone include:
- feeling tired
- rash
- pain in muscles, bones, and joints
- itchy skin
- diarrhea
- nausea
- weakness
- cough
- vomiting
- shortness of breath
- constipation
- decreased appetite
- back pain
- upper respiratory tract infection
- fever
- headache
- stomach-area (abdominal) pain
- urinary tract infection
The most common side effects of OPDIVO when used in combination with YERVOY include:
- feeling tired
- diarrhea
- rash
- itching
- nausea
- pain in muscles, bones, and joints
- fever
- cough
- decreased appetite
- vomiting
- stomach-area (abdominal) pain
- shortness of breath
-
upper respiratory tract
infection - headache
-
low thyroid hormone
levels (hypothyroidism) - constipation
- decreased weight
- dizziness
The most common side effects of OPDIVO when used in combination with YERVOY and chemotherapy include:
- feeling tired
- pain in muscles, bones, and joints
- nausea
- diarrhea
- rash
- decreased appetite
- constipation
- itching
The most common side effects of OPDIVO when used in combination with chemotherapy include:
- nausea
- constipation
- feeling tired
- decreased appetite
- rash
The most common side effects of OPDIVO when used in combination with cabozantinib include:
- diarrhea
- feeling tired or weak
- liver problems
- rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet
- mouth sores
- rash
- high blood pressure
- low thyroid hormone levels
- pain in muscles, bones, and joints
- decreased appetite
- nausea
- change in the sense of taste
- stomach-area (abdominal) pain
- cough
- upper respiratory tract infection
The most common side effects of OPDIVO when used in combination with fluoropyrimidine and platinum-containing chemotherapy include:
- nausea
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- constipation
- mouth sores
- diarrhea
- vomiting
- stomach-area (abdominal) pain
- pain in muscles, bones, and joints
These are not all the possible side effects.
Talk to your healthcare team or pharmacist for
more information. You are encouraged to report side effects of
prescription drugs to the FDA. Call
What should I discuss with my healthcare team before receiving OPDIVO or YERVOY?
Tell your healthcare provider about all your medical conditions, including if you:
- have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area in the past and have received other medicines that are like OPDIVO
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if OPDIVO or YERVOY passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of OPDIVO or YERVOY.
Females who are able to become pregnant:
Your healthcare provider should do a pregnancy test before you start receiving OPDIVO or YERVOY.
-
You should use an effective method of birth control
during your treatment and for
5 months after the last dose of OPDIVO or YERVOY. Talk to your healthcare provider about birth control methods that you can use during this time. -
Tell your healthcare provider right away if you become
pregnant or think you may be pregnant during treatment
with OPDIVO or YERVOY. You or your healthcare provider
should contact
Bristol Myers Squibb at1-844-593-7869 as soon as you become aware of a pregnancy.
Tell your healthcare provider about all the medicines you take, including:
- prescription medicines
- over-the-counter medicines
- vitamins
- herbal supplements
For more information, please see U.S. Full Prescribing Information and Medication Guide for OPDIVO.
Information provided on this website is not a substitute for
talking with your healthcare professional.
Your healthcare professional is the
best source of information about your disease.
All individuals depicted are models used for illustrative purposes only.
You are now leaving this Bristol Myers Squibb site
This internet site may provide links or references to other sites. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Would you like to leave this site?
You are about to leave this Bristol Myers Squibb site. You are being redirected to another Bristol Myers Squibb site.
Would you like to leave this site?